Tech Company Financing Transactions
MimiVax Funding Round
On 8/28/2015, MimiVax announced $1.6 million in funding from private investors.
Transaction Overview
Company Name
Announced On
8/28/2015
Transaction Type
Venture Equity
Amount
$1,550,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Elm & Carlton St. MRC 105
Buffalo, NY 14263
USA
Buffalo, NY 14263
USA
Phone
Website
Email Address
Not Recorded
Overview
MimiVax is commercializing intellectual property developed at Roswell Park Cancer Institute (RPCI) through bench to bedside clinical translation. We are developing immunotherapeutic vaccines and targeted therapies for cancer treatment. SurVaxM is our lead drug pipeline agent.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Ciesielski
Chief Medical Officer
Robert Fenstermaker
VP - Bus. Development
Anil Goyal
VP - General Counsel
Scott Friedman
Browse more venture capital transactions:
Prev: 8/27/2015: Sonavation venture capital transaction
Next: 8/28/2015: Viakoo venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs